Results 111 to 120 of about 599,459 (163)

Dyslipidemia in osteoarthritis: A study combining bibliometric analysis and retrospective data mining. [PDF]

Medicine (Baltimore)
Chen X, Liu J, Wang G.
europepmc   +1 more source

The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a predictor of NAFLD prevalence and steatosis severity. [PDF]

Sci Rep
Liu Y, Wang R.
europepmc   +1 more source

Relationship between albumin and osteoporosis in patients with type 2 diabetes mellitus. [PDF]

Front Endocrinol (Lausanne)
Zhao H, Qi C, Zhang Y, Yang L, Ren L, Chen S.   +5 more
europepmc   +1 more source

Correlation between conventional and unconventional lipid parameters with the risk of progression of renal function decline: insights from the China Health and Retirement Longitudinal Study 2011-2015. [PDF]

Ren Fail
Xin Y, Wang Y, Shu Y, Liang H, Yang Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lipoproteins and Lipoprotein Metabolism

1975
The plasma lipoproteins provide the body with a transport system for the otherwise insoluble lipids. All lipids except for free fatty acids and lysolecithin, circulate in plasma from their site of origin to their site of utilization in association with these lipid-protein complexes, the lipoproteins. In healthy humans, more than 100 g of triglycerides,
S. Eisenberg, R. I. Levy
openaire   +2 more sources

Lipoprotein Apheresis

Endocrinology and Metabolism Clinics of North America, 2015
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients ...
Patrick M, Moriarty, Linda, Hemphill
openaire   +3 more sources

Endocytosis of lipoproteins

Atherosclerosis, 2018
During their metabolism, all lipoproteins undergo endocytosis, either to be degraded intracellularly, for example in hepatocytes or macrophages, or to be re-secreted, for example in the course of transcytosis by endothelial cells. Moreover, there are several examples of internalized lipoproteins sequestered intracellularly, possibly to exert ...
Paolo Zanoni, Srividya Velagapudi, Mustafa Yalcinkaya, Lucia Rohrer, Arnold von Eckardstein   +4 more
openaire   +4 more sources

The Biochemistry of Lipoproteins

Journal of Inherited Metabolic Disease, 1988
SummaryLipids are transported in the blood in four major classes of lipoproteins. The triacylglycerol‐rich lipoproteins are chylomicrons and very‐low‐density lipoproteins (VLDL) which are produced by the small intestine and liver, respectively. These lipoproteins mainly carry fatty acids to adipose tissue and muscle where the triacylglycerol is ...
David N. Brindley, Andrew M. Salter
openaire   +3 more sources

Lipoprotein (a)

Baillière's Clinical Endocrinology and Metabolism, 1995
Lipoprotein (a) is similar to low-density lipoprotein but is unique in having an additional apolipoprotein called apolipoprotein (a) (apo(a)) covalently linked to it. apo(a), which is a member of the plasminogen gene superfamily, has a protease domain which cannot be activated to cause fibrinolysis.
openaire   +2 more sources

Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease

Journal of Clinical Lipidology, 2019
Elevated lipoprotein(a) [Lp(a)] is an independent risk factor for cardiovascular disease (CVD). In the United States, lipoprotein apheresis (LA) therapy is approved for patients with familial hypercholesterolemia. Germany uses LA therapy for patients with an Lp(a) > 60 mg/dL, normal low-density lipoprotein cholesterol (LDL-C) levels, and CVD.
Patrick M. Moriarty, Lauryn K. Gorby, Jessica V. Gray   +2 more
openaire   +3 more sources